Dogs with epilepsy that are receiving conventional anticonvulsants and having at least two seizures per month.  Upon enrollment, every dog will be evaluated by a neurologist and any medication adjustments will be made prior to starting the trial.

 

 

The aim of this study is to assess the efficacy of a component of the Cannabis sativa plant, cannabidiol (CBD), in treating canine epilepsy. The CBD product is very low in the psychoactive component of cannabis, THC, making it safe for use in dogs. Each dog will be randomly assigned to receive either CBD or a placebo for 12 weeks and then switch to the opposite medication for an additional 12 weeks.

 

 

 

All costs related to the study will be covered in full, including the examinations, MRI, spinal tap, bloodwork and the CBD oil.

 

 

Interested participants can learn more by contacting one of our research technicians by emailing CSUNeuroTrials@colostate.edu or by calling (970) 305-0455. You can also click here to take a quick survey and find out if your pet qualifies.